Compare Citius Pharmaceuticals Inc (CTXR) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs JD.Com Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while JD.Com Inc trades at $26.95 (market cap $36.51B). The key difference: JD.Com Inc is far larger — about 2647.6× Citius Pharmaceuticals Inc's market cap, and JD.Com Inc pays a 3.7% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and JD.Com Inc for 85 Days on average.
| CTXR | JD | |
|---|---|---|
Market Cap | $13.79M | $36.51B |
Volume | 156,684 | 7,051,146 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $34.53 |
52-Week Low | $0.48 | $25.19 |
Typical Hold Time | 16 Days | 85 Days |
Enterprise Value | $3.96M | $19.16B |
Dividend Yield | — | 3.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
JD.com trades at $26.91, up 1.55% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.93 surpassing the $0.86 estimate. The company maintains robust fundamentals, including a low P/S ratio of 0.2 and a solid cash position of $234 billion as of 2024. Positive developments include potential EU approval for the $2.5 billion Ceconomy acquisition, signaling strategic expansion.
The outlook for JD.com is positive, supported by undervaluation metrics and strong free cash flow, though risks include revenue declines and regulatory scrutiny. With 69.57% of analysts rating it a Buy and a consensus price target of $35.86, the stock offers significant upside potential, but investors should monitor competitive pressures and macroeconomic headwinds in the Chinese market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
